Urologix to Host Its Fiscal 2010 First Quarter Conference Call

• Press Release
• Source: Urologix, Inc.
• On 4:24 pm EDT, Wednesday October 21, 2009

MINNEAPOLIS--(BUSINESS WIRE)--Urologix^®, Inc. (Nasdaq:ULGX - News) will host a conference call to present fiscal 2010 first quarter results on Tuesday, October 27, 2009 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-783-2143 and enter the Participant Passcode 50068778 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Stryker Warren, Jr., Chief Executive Officer, will host the call.

Related Quotes

Symbol	Price	Change
ULGX	0.98	+0.04

{"s" : "ulgx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until November 2, 2009 at 4:00 p.m. CT (5:00 p.m. ET). To listen to the replay, please dial 1-888-286-8010 and enter the Participant Passcode 83107164.

The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (www.streetevents.com).

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix’ products include the CoolWave®, Targis® and Prostatron® control units and the CTC Advance™, Cooled ThermoCath® , Targis® and Prostaprobe® catheter families. All of Urologix’ products utilize Cooled ThermoTherapy™- targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.

Urologix, Inc.
Melanie Hill, Office Manager, 763-475-7682
mhill@urologix.com